Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose The aim of this study was to confirm the efficacy and safety of regorafenib for advanced gastrointestinal stromal tumors (GISTs) reported in the GRID phase III trial in Korean patients. Materials and Methods Fifty-seven Korean patients with advanced GIST who experienced both imatinib and sunitinib failure were enrolled in the management access program between December 2012 and November 2013 and treated with regorafenib (160 mg orally once daily in a 3 weeks on /1 week off). Results None of the patients achieved a complete or partial response while 25 patients (44%) showed stable disease for 12 weeks. With a median follow-up of 12.7 months (range, 0.2 to 27.6 months), the median progression-free survival and overall survival were 4.5 months (95% confidence interval [CI], 3.8 to 5.3) and 12.9 months (95% CI, 8.1 to 17.7), respectively. Interestingly, 15 patients (26%) experienced an exacerbation of their cancer-related symptoms (abdominal pain in eight and abdominal distension in five) during the rest period for regorafenib, but all were ameliorated upon the resumption of regorafenib. The most common grade 3 or 4 adverse event was a hand-foot skin reaction (25%). The regorafenib dose was reduced in 44 patients (77%) due to toxicity, which manifested mainly as a handfoot skin reaction (n=31). Conclusion This study confirmed the efficacy and safety of regorafenib for advanced GIST after imatinib and sunitinib failure in Korean patients. Considering the exacerbation of the cancer-related symptoms observed during the rest periods, further exploration of the continuous dosing schedule of regorafenib is warranted in future clinical trials.
Abstract
Purpose The aim of this study was to confirm the efficacy and safety of regorafenib for advanced gastrointestinal stromal tumors (GISTs) reported in the GRID phase III trial in Korean patients. Materials and Methods Fifty-seven Korean patients with advanced GIST who experienced both imatinib and sunitinib failure were enrolled in the management access program between December 2012 and November 2013 and treated with regorafenib (160 mg orally once daily in a 3 weeks on /1 week off). Results None of the patients achieved a complete or partial response while 25 patients (44%) showed stable disease for 12 weeks. With a median follow-up of 12.7 months (range, 0.2 to 27.6 months), the median progression-free survival and overall survival were 4.5 months (95% confidence interval [CI], 3.8 to 5.3) and 12.9 months (95% CI, 8.1 to 17.7), respectively. Interestingly, 15 patients (26%) experienced an exacerbation of their cancer-related symptoms (abdominal pain in eight and abdominal distension in five) during the rest period for regorafenib, but all were ameliorated upon the resumption of regorafenib. The most common grade 3 or 4 adverse event was a hand-foot skin reaction (25%). The regorafenib dose was reduced in 44 patients (77%) due to toxicity, which manifested mainly as a handfoot skin reaction (n=31). Conclusion This study confirmed the efficacy and safety of regorafenib for advanced GIST after imatinib and sunitinib failure in Korean patients. Considering the exacerbation of the cancer-related symptoms observed during the rest periods, further exploration of the continuous dosing schedule of regorafenib is warranted in future clinical trials.
참고문헌 (19)
- Fletcher CD, "Diagnosis of gastrointestinal stromal tumors : a consensus approach", Hum Pathol, 33, pp.459~465 (2002)
- Corless CL, "KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size", Am J Pathol, 160, pp.1567~1572 (2002)
- Heinrich MC, "PDGFRA activating mutations in gastrointestinal stromal tumors", Science, 299, pp.708~710 (2003)
- Heinrich MC, "Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor", J Clin Oncol, 21, pp.4342~4349 (2003)
- Demetri GD, "Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors", N Engl J Med, 347, pp.472~480 (2002)
- Joensuu H, "Management of malignant gastrointestinal stromal tumours", Lancet Oncol, 3, pp.655~664 (2002)
- Debiec-Rychter M, "Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412inhibitor against imatinib-resistant mutants", Gastroenterology, 128, pp.270~279 (2005)
- Demetri GD, "Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib : a randomised controlled trial", Lancet, 368, pp.1329~1338 (2006)
- Heinrich MC, "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor", J Clin Oncol, 26, pp.5352~5359 (2008)
- Wilhelm SM, "Regorafenib(BAY 73-4506) : a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity", Int J Cancer, 129, pp.245~255 (2011)
- George S, "Efficacy and safety of regorafenib in patients with metastatic and", or unresectable GI stromal tumor after failure of imatinib and sunitinib : a multicenter phase II trial, 2012, pp.30, 2401~2407
- Demetri GD, "Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib(GRID) : an international, multicentre, randomised, placebo-controlled, phase 3 trial", Lancet, 381, pp.295~302 (2013)
- Komatsu Y, "Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment : a subgroup analysis evaluating Japanese patients in the phase III GRID trial", Int J Clin Oncol, 20, pp.905~912 (2015)
- Kang YK, "Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib(RIGHT) : a randomised, placebo-controlled, phase 3trial", Lancet Oncol, 14, pp.1175~1182 (2013)
- Demetri GD, "An updated overall survival analysis with correction for protocol-planned crossover of the international, phase III, randomized, placebo-controlled trial of regorafenib in advanced gastrointestinal stromal tumors after failure of imatinib and sunitinib (GRID)", J Clin Oncol, 33(Suppl 3) (2015)
- Poole CD, "Health utility of patients with advanced gastrointestinal stromal tumors(GIST)after failure of imatinib and sunitinib : findings from GRID, a randomized, double-blind, placebo-controlled phase III study of regorafenib versus placebo", Gastric Cancer, 18, pp.627~634 (2015)
- Kajiura S, "A case of a gastrointestinal stromal tumor of the rectum effectively treated with continuously-administered regorafenib after failure of imatinib and sunitinib", Nihon Shokakibyo Gakkai Zasshi, 113, pp.655~661 (2016)
- D'Alessandro R, "Reversibility of regorafenib effects in hepatocellular carcinoma cells", Cancer Chemother Pharmacol, 72, pp.869~877 (2013)
- Shimizu T, "Phase I dose-escalation study of continuously administered regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors", J Clin Oncol, 28(15s) (2010)